Reportlinker Adds Triple Analysis: Leukemia, Lung Cancer and Cancer Vaccines

Oct 19, 2010, 14:07 ET from Reportlinker

NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Leukemia, Lung Cancer and Cancer Vaccines

http://www.reportlinker.com/p0284982/Triple-Analysis-Leukemia-Lung-Cancer-and-Cancer-Vaccines.html

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia

The leukemia report part comprises defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. This report part extensively analyses 136 identified targets of leukemia drugs, organized into 115 drug target strategies, and assesses them in leukemia.

This part is based on the following publication:

Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

Part II: Lung Cancer

The lung cancer report part includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). This report part extensively analyses 182 identified targets of lung cancer drugs, organized into 173 drug target strategies, and assesses them in lung cancer.

This part is based on the following publication:

Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

Part III: Cancer Vaccines

The cancer vaccine report part comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. This part extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications.

This part is based on the following publication:

Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia

5 Introduction 22

6 Single Drug Target Benchmarking from the Leukemia Pipeline (136 Drug Targets) 25-265

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Combinations Identified in the Leukemia Pipeline? (115 Drug Target Strategies and 175 Drugs) 266-293

8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Pipeline by Type of Compound (7 Different Compound Strategies) 294-324

9 Portfolio Planning: Competitive Benchmarking of Leukemia Pipeline by Investigator (126 Investigators) 325-513

11 Drug Index 515

12 Company Index 519

Figures: Includes 7 Figures

Tables: Includes 156 Tables

Total Number of Pages: 522

Part II: Lung Cancer

5.1 The Scope of this Report 27

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (182 Drug Targets) 31-323

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lung Cancer Pipeline? (173 Drug Target Strategies and 283 Drugs) 324-368

8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Pipeline by Type of Compound (7 Different Compound Strategies) 369-419

9 Selecting a Sub-Indication of Lung Cancer for Drug Development 420-462

10 Portfolio Planning: Competitive Benchmarking of Lung Cancer Pipeline by Investigator (167 Investigators) 463-751

12 Drug Index 753

13 Company Index 761

Figures: Includes 13 Figures

Tables: Includes 227 Tables

Total Number of Pages: 596

Part III: Cancer Vaccines

5.1 The Scope of this Report 26

6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets) 30-194

7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs) 195-308

8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 309-338

9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications) 339-386

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators) 387-649

11 Disclaimer 650

12 Drug Index 651

13 Company Index 656

Figures: Includes 6 Figures

Tables: Includes 205 Tables

Total Number of Pages: 659

To order this report:

Drug Discovery and Development Industry: Triple Analysis: Leukemia, Lung Cancer and Cancer Vaccines

Drug Discovery and Development Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com